Opinion

Podcast

A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

To watch the video series component of this episode, click here.

00:00 Introductions

02:10 The impact of plaque psoriasis

07:48 Absence of treatment or under treatment of plaque psoriasis

12:50 Prescribing novel systemic medications in plaque psoriasis as an advanced practice provider

15:46 Classifying moderate disease in plaque psoriasis

19:43 Getting payer approval for your patients with plaque psoriasis

23:18 Novel oral systemic treatments for plaque psoriasis

25:03 Pivotal clinical trial data on deucravacitinib

27:58 Deciding on aprimilast versus deucravacitinib for your patients with plaque psoriasis

31:53 Mechanism of action of deucravacitinib

38:13 Selecting a therapy in the evolving treatment landscape for your patient with plaque psoriasis

43:08 Educating your patients on injectables and orals systemic treatments

46:58 Summary

Related Videos
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
How to Address Blistering Diseases, with Donna Culton, MD, PhD
Differentiating Between Different Types of Alopecia, with Jerry Shapiro, MD
Julie Harper, MD: Discussing Acne Treatment Updates, Unmet Needs Among Patients
Review of Recent Advancements in Dermatology, with Matthew Zirwas, MD
Raj Chovatiya, MD, PhD: Treating Hidradenitis Suppurativa with IL-17, JAK Inhibitors
© 2024 MJH Life Sciences

All rights reserved.